This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - beta interferon for the treatment of multiple sclerosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Glatiramer acetate is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and
    • the company provides it according to the commercial arrangement

  • Interferon beta-1a is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and
    • the companies provide it according to commercial arrangement

  • Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and has had 2or more relapses within the last 2 years or
    • the person has secondary progressive multiple sclerosis with continuing relapses
    • and the company provides it according to the commercial arrangement.

Reference:

(1) NICE (June 2018). Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Web: www.nice.org.uk

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.